- September 6, 2018
- Posted by: PharmaScroll
MediciNova announced that the New England Journal of Medicine has published results of the SPRINT-MS Phase 2b trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS).
“These findings are significant for patients with progressive MS,” says Robert Fox, M.D., the study’s principal investigator and vice-chair for research in Cleveland Clinic’s Neurological Institute. “Our hope is that the benefit of ibudilast in slowing brain shrinkage will also translate to decreased progression of associated physical disabilities in a future Phase 3 trial.”
Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc. commented, “We are very pleased that results of this important study were published in the New England Journal of Medicine. We thank the NIH, the investigators, and the National Multiple Sclerosis Society. We look forward to moving on to Phase 3 and we are currently preparing for the end-of-Phase 2 meeting with FDA. With a convenient oral administration, a very favorable safety and tolerability profile, and the potential for better efficacy than other drugs for progressive MS, we believe ibudilast could become the best-in-disease drug.”
Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.
To read more news about Multiple Sclerosis, visit https://pharmascroll.com/news-category/multiple-sclerosis/
News Source: MediciNova Website
Image Source: https://www.finance-monthly.com/2017/08/gail-adinamis-and-the-leading-global-provider-of-ambulant-healthcare-services-for-clinical-trials/